Nucala vs Daliresp
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
| US Nucala | US Daliresp | |
|---|---|---|
| Generic name | mepolizumab | roflumilast |
| Drug class | IL-5 Antagonist (Biologic) | PDE4 Inhibitor (Oral) |
| Treats | Severe eosinophilic asthma, COPD, nasal polyps | Chronic obstructive pulmonary disease (COPD) |
| Category | Respiratory | Respiratory |
| Manufacturer | GSK | AstraZeneca |
| Year approved | 2015 | 2011 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $75M | — |
| Common side effects | Headache, Injection site reactions, Back pain, Fatigue | Diarrhea, Weight loss, Nausea, Headache |
Frequently asked questions
Is Nucala or Daliresp better?
Neither is universally "better." Nucala (mepolizumab) and Daliresp (roflumilast) are both used for respiratory, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Nucala and Daliresp?
Nucala is a IL-5 Antagonist (Biologic) made by GSK, while Daliresp is a PDE4 Inhibitor (Oral) made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Nucala has the larger estimated TV advertising budget of the two.